ERBB2 and neoplasm: Furthermore, this inhibition resulted in enhanced anti-tumour effects of anti-erbB2/neu monoclonal antibody targeted therapy in Balb/c mice having CT26Her2 tumours by inhibiting regulatory T cells function and induction of tumour immunity (Nagai et al., 2019).